Cynthia Evans
Payments from drug & device makers
Across 109 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$312
- Novo Nordisk$278
- AstraZeneca$185
- Lilly USA, LLC$172
- Boehringer Ingelheim$145
- Amgen$141
- plus $627 from 20 others
What the payments were for
- Food & beverage$1,67790%
- Education$18410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 10 | $312 |
| Novo Nordisk | 24 | $278 |
| AstraZeneca(2 entities) | 11 | $185 |
| Lilly USA, LLC | 11 | $172 |
| Boehringer Ingelheim | 9 | $145 |
| Amgen(2 entities) | 7 | $141 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Bayer | 4 | $60 |
| Abbott | 3 | $55 |
| Merck | 3 | $51 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| AbbVie | 2 | $38 |
| Pfizer | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $35 |
| Johnson & Johnson | 2 | $29 |
| Novartis | 2 | $27 |
| GSK | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Biogen | 1 | $21 |
| Dexcom, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Organogenesis Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$1,860 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 270 | $70,670 |
| JardianceEmpagliflozin | 204 | $50,073 |
| OzempicSemaglutide | 40 | $40,760 |
| TrulicityDulaglutide | 34 | $35,560 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,458 |
| MounjaroTirzepatide | 12 | $15,138 |
| MyrbetriqMirabegron | 51 | $10,868 |
| Sucralfate | 44 | $9,587 |
| FarxigaDapagliflozin Propanediol | 29 | $8,883 |
| LinzessLinaclotide | 12 | $6,926 |
| Aripiprazole | 35 | $6,659 |
| XareltoRivaroxaban | 16 | $6,585 |
| EntrestoSacubitril/Valsartan | 12 | $5,016 |
| JanuviaSitagliptin Phosphate | 24 | $4,082 |
| Gabapentin | 453 | $3,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $70,670270 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $172 | $52,12265 claims |
| Boehringer IngelheimJardiance | $145 | $50,073204 claims |
| Novo NordiskOzempic | $278 | $40,76040 claims |
| GSKTrelegy Ellipta | $27 | $16,45820 claims |
| Astellas Pharma US IncMyrbetriq | $312 | $10,86851 claims |
| AstraZenecaFarxiga | $185 | $8,88329 claims |
| AbbVieLinzess | $38 | $6,92612 claims |
| Johnson & JohnsonXarelto | $29 | $6,58516 claims |
| NovartisEntresto | $27 | $5,01612 claims |
| MerckJanuvia | $51 | $4,08224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.
Other family in Caro
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.